The global cell banking outsourcing market is booming, valued at USD 14.37 billion in 2024, growing to USD 16.72 billion in 2025, and projected to hit approximately USD 63.49 billion by 2034 at a robust CAGR of 16.37% (2025–2034). This rapid expansion is driven by rising demand for cell-based biologics, regenerative therapies, and advanced outsourcing services enabling pharma companies to reduce operational burdens and access cutting-edge technologies.
Market Size 2024: USD 14.37 Billion
Forecast 2034: USD 63.49 Billion
CAGR (2025–2034): 16.37%
Regional Leaders: North America (dominant, 40–45% share)
Fastest-Growing Region: Asia Pacific (highest CAGR 2025–2035)
Key Segment: Master Cell Bank (36–40% share in 2024)
Below, we highlight leading companies in the cell banking outsourcing market, showcasing their profiles, products, and market positioning.
About: A global leader in contract development and manufacturing, AGC Biologics offers comprehensive services for biologics and cell therapies.
Products: Cell therapy development, cGMP manufacturing, viral vector production.
Market Cap: Estimated at USD 1.2 billion.
About: A trusted name in genetic material production for the biotech and pharmaceutical industries.
Products: Plasmid DNA, mRNA, proteins for research, clinical, and commercial use.
Market Cap: Part of Danaher Corporation (Danaher Market Cap: USD 210+ billion).
About: BioReliance, a Merck KGaA company, specializes in biologics safety testing and manufacturing support.
Products: Master cell bank manufacturing, testing, and characterization.
Market Cap: Merck KGaA Market Cap: ~USD 90 billion.
About: Sartorius-owned BioOutsource provides biologics testing and biosimilar characterization services.
Products: Analytical testing, biosafety testing, and cell banking services.
Market Cap: Sartorius AG Market Cap: ~USD 20 billion.
About: UK-based organization accelerating the growth of the cell and gene therapy industry.
Products: Process development, manufacturing support, and cell banking.
Market Cap: Government-supported entity (non-listed).
About: A global CRO offering preclinical and clinical laboratory services for pharmaceuticals.
Products: Cell banking, biologics testing, and cGMP production.
Market Cap: Approx. USD 12 billion.
About: A leading provider of bioanalytical and genomic testing services worldwide.
Products: Biologics testing, cell bank characterization, and release testing.
Market Cap: USD 15+ billion.
About: A CDMO delivering end-to-end solutions in biologics manufacturing.
Products: Cell bank production, viral vectors, and biologics development.
Market Cap: Part of Fujifilm Holdings (Market Cap: ~USD 70 billion).
About: A top CDMO helping pharma and biotech firms with biologics and cell therapy production.
Products: Master cell banking, biosafety testing, and large-scale manufacturing.
Market Cap: Approx. USD 35 billion.
About: Division of Novartis offering contract manufacturing solutions for advanced therapies.
Products: Cell banking, gene therapy manufacturing, and biologics support.
Market Cap: Novartis Market Cap: ~USD 200 billion.
About: Acquired by Catalent, Paragon focuses on viral vectors and gene therapies.
Products: Cell and gene therapy manufacturing, banking, and development.
Market Cap: Catalent Market Cap: USD 10+ billion.
About: A CDMO specializing in advanced therapies and biologics.
Products: Cell banking, viral vector production, and analytical testing.
Market Cap: Private company (financials undisclosed).
About: Offers analytical services, including cell line characterization and banking.
Products: Biosafety testing, master and working cell bank production.
Market Cap: Private company.
About: German-based CDMO providing end-to-end biopharmaceutical manufacturing solutions.
Products: Cell banking, process development, and biologics production.
Market Cap: Private company.
About: A global powerhouse in biopharmaceutical manufacturing and outsourcing.
Products: Cell banking, large-scale biologics production, and biosafety testing.
Market Cap: Approx. USD 60 billion.
About: Provides biological research materials and services worldwide.
Products: Recombinant proteins, antibodies, and cell banking services.
Market Cap: Approx. USD 4 billion.
About: India-based CRO/CDMO supporting global pharma and biotech companies.
Products: Cell line development, banking, and biologics testing.
Market Cap: Approx. USD 2 billion.
About: Industry leader providing comprehensive pharma services through Patheon.
Products: Master cell bank manufacturing, biosafety testing, and cGMP production.
Market Cap: USD 220+ billion.
Request a customized case study tailored to your business needs and gain deeper insights
into healthcare market strategies: sales@towardshealthcare.com
1. What is cell banking outsourcing?
Cell banking outsourcing involves third-party services for creating, storing, and managing cell banks for biologics and cell-based therapies.
2. Which region leads the cell banking outsourcing market?
North America dominates the market with a 40–45% share in 2024.
3. What is the expected CAGR for the market?
The market is projected to grow at a CAGR of 16.37% between 2025 and 2034.
4. Which company has the largest market share?
Companies like Lonza, Samsung Biologics, and Thermo Fisher Scientific are leading players in the market.
5. Why is Asia Pacific the fastest-growing region?
Due to rising healthcare investments, supportive government initiatives, and growing demand for cell-based therapies.
Source : https://www.towardshealthcare.com/insights/cell-banking-outsourcing-market-sizing
Invest in Our Premium Strategic Solution: https://www.towardshealthcare.com/price/5872
Asia-Pacific is poised to become the fastest-growing region in the small-scale bioreactors market over the coming years, driven by several… Read More
North America continues to dominate the global neurostimulation devices market, holding a significant 60% share in 2024. Several key factors… Read More
AAVnerGene Inc., an innovative biotech company based in Rockville, MD, known for its cutting-edge AAV tissue-targeted delivery and manufacturing technologies,… Read More
Jiangsu Hengrui Pharmaceuticals Co., Ltd. and IDEAYA Biosciences, Inc. are set to showcase their groundbreaking research at the IASLC 2025… Read More
QIAGEN has launched its new QIAseq xHYB long-read panels, a cutting-edge solution designed to explore the complexities of genomically diverse… Read More
Kyoto, Japan July 2025 A groundbreaking collaboration has been formed between Kansai Startup Academia Coalition (KSAC), led by Kyoto University,… Read More